Weekly NADAC Price Changes
A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.
- Published NDCs
- 30,095
- Price increases
- 14,883
- Price decreases
- 13,829
- Unchanged prices
- 1,280
NADAC Week of Oct 21: Balanced Price Movement Masks Concentrated Spikes in Biologics and Glucagon
The October 21, 2026 NADAC release covered 30,095 NDCs, with 29,992 eligible for week-over-week comparison. Of these, 28,712 (95.7%) changed price, split nearly evenly between 14,883 increases and 13,829 decreases, alongside 1,280 unchanged NDCs and 103 without a prior comparison. This near-even split signals broad repricing activity rather than a directional market-wide trend. The largest single dollar movements were concentrated in a handful of specialty products: a $1.8M increase tied to a single Ofatumumab (Kesimpta) NDC and a $853.2K decline led by Glucagon products, particularly the Amphastar emergency kit (-12.8%). Manufacturer-level activity shows Novartis and AbbVie posting the largest aggregate upward swings ($1.9M and $1.2M respectively) across dozens of products, while Amphastar and Prasco Laboratories saw net declines. Therapeutic class data shows the top class by dollar impact, CD20-directed Cytolytic Antibody, reflects just one drug, underscoring that headline-level 'most pressured class' figures can be driven by a single product rather than category-wide pressure. In contrast, broader classes like alpha-Adrenergic Agonist (252 drugs) and Progestin (125 drugs) show more distributed movement, better reflecting true market breadth this week.
Key takeaways
- Overall activity was balanced (14,883 increases vs. 13,829 decreases out of 28,712 changed NDCs), indicating normal repricing churn rather than a systemic inflationary or deflationary trend this week.
- The two largest dollar movers—Ofatumumab's $1.8M increase and Glucagon's $853.2K decline—are each concentrated in one or few NDCs, so they should not be read as indicators of broader specialty or generic injectable market direction.
- Breadth matters: classes like alpha-Adrenergic Agonist (252 drugs, +0.5% avg move, $665K impact) and Progestin (125 drugs) show more NDCs moving in tandem, making them more representative of genuine category-level cost pressure than the single-drug CD20 antibody class.
What to watch
Kesimpta (Ofatumumab) single-NDC concentration
The $1.8M 'Most pressured class' designation for CD20-directed Cytolytic Antibody stems entirely from one Kesimpta NDC (+0.2%). Payers should monitor whether this reflects a one-time list adjustment or the start of a broader biologic repricing pattern next cycle.
Glucagon category under sustained pressure
Glucagon fell -7.5% on average across 7 NDCs (-$1.0M impact), led by a -12.8% move on Amphastar's emergency kit. With 16 Amphastar products net negative (-$906.6K), procurement teams should reassess glucagon contract pricing and emergency-kit sourcing in the near term.
Broad-based alpha-Adrenergic Agonist and AbbVie movement
Across 252 drugs, alpha-Adrenergic Agonist rose +0.5% ($665K impact), and AbbVie posted $1.2M in aggregate increases across 68 products. These wider-footprint moves are more likely to affect formulary cost baselines than single-NDC spikes and warrant closer tracking into next week's release.
Largest cost pressure
Largest absolute weekly price increase in the current release
Largest relief
Largest absolute weekly price decline in the current release
Largest manufacturer swing
Largest aggregate movement across tracked NDCs
Top 10 NDCs by weekly price movement
Up to 10 changed products are shown. Each edition preserves its published price comparison.
| Drug | Manufacturer | NDC | Prev. price | Current price | Change |
|---|---|---|---|---|---|
| KESIMPTA 20 MG/0.4 ML PEN | Novartis Pharmaceuticals Corporation | 00078100768 | $24,369.3694 | $24,411.0944 | +0.2% |
| SKYRIZI 150 MG/ML PEN | AbbVie Inc. | 00074210001 | $22,774.3609 | $22,795.0931 | +0.1% |
| GLUCAGON 1 MG EMERGENCY KIT | Amphastar Pharmaceuticals, Inc. | 00548585000 | $154.2034 | $134.4583 | -12.8% |
| UZEDY ER 100 MG/0.28 ML SYRING | Teva Pharmaceuticals USA Inc. | 51759052010 | $9,389.0861 | $9,371.3414 | -0.2% |
| UZEDY ER 125 MG/0.35 ML SYRING | Teva Pharmaceuticals USA Inc. | 51759063010 | $9,329.0048 | $9,343.0636 | +0.2% |
| NORELGESTROM-EE 150-35 MCG/DAY | Zydus Pharmaceuticals (USA) Inc. | 70710119003 | $33.2895 | $31.3170 | -5.9% |
| DUPIXENT 300 MG/2 ML PEN | Sanofi-Aventis U.S. LLC | 00024591502 | $1,009.5592 | $1,008.9404 | -0.1% |
| INVEGA SUSTENNA 156 MG/ML SYRG | Janssen Pharmaceuticals Inc. | 50458056301 | $2,337.7083 | $2,336.3071 | -0.1% |
| TALTZ 80 MG/ML AUTOINJECTOR | Eli Lilly and Company | 00002144511 | $7,370.7151 | $7,366.5697 | -0.1% |
| ABILIFY MAINTENA ER 400 MG SYR | Otsuka America Pharmaceutical Inc. | 59148007280 | $2,853.2457 | $2,852.0013 | -0.0436% |
Drug market summaries
Manufacturer movement
Notes and methodology
How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.
Publication comparison
Prices are compared between the two CMS publication dates shown above, using weekly history snapshots. An unchanged effective date does not mean a publication is missing. NDCs absent from the previous publication are excluded from change calculations; missing prices are not counted as unchanged.
Top mover ranking
The Top 10 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available. The current release had 28,712 NDCs with a measurable publication-to-publication change.
Segment summaries
Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using dispensing-volume exposure when the volume table is available.
Headline cards and archive stability
In editions with headline cards, most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.
More archived editions
Each edition is permanently archived under its release date.
Week of October 14, 2026
NADAC weekly update: no price changes among comparable NDCs — 2026-10-14
The CMS publication dated 2026-10-14 contains 30,031 priced NDCs in our data. Of the 30,027 NDCs also priced in the 2026-10-07 publication, 0 changed and 30,027 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Week of October 7, 2026
NADAC weekly update: 2 NDCs changed — 2026-10-07
The CMS publication dated 2026-10-07 contains 30,048 priced NDCs in our data. Of the 29,987 NDCs also priced in the 2026-09-30 publication, 2 changed and 29,985 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Week of September 30, 2026
NADAC weekly update: 14 NDCs changed — 2026-09-30
The CMS publication dated 2026-09-30 contains 30,079 priced NDCs in our data. Of the 29,945 NDCs also priced in the 2026-09-23 publication, 14 changed and 29,931 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
Explore the broader trend ecosystem
Trends overview
Broader market movement and volatility across the full NADAC dataset.
Manufacturers
Compare suppliers and pricing dispersion across product portfolios.
Drug markets
Review generic alternatives by therapeutic market and current pricing.
Therapeutic classes
See category-level swings by prescribing class and market segment.
Understanding NADAC pricing
A primer on how NADAC works and why weekly movement matters.
Methodology
How the data is normalized and aggregated for public reporting.